<DOC>
	<DOCNO>NCT02170987</DOCNO>
	<brief_summary>To investigate dabigatran clinically relevant impact cardiac electrophysiology manifest prolongation QT-interval .</brief_summary>
	<brief_title>Assessment Electrophysiological Effects Dabigatran Etexilate Single Dose QT Interval Healthy Female Male Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy female ( least 1/3 ) male ( least 1/3 ) volunteer determine result screen accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , HR ) , 12lead ECG , clinical laboratory test 2 . Age &gt; = 18 Age &lt; = 65 year 3 . BMI &gt; = 20.0 BMI &lt; =29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation 1 . Any finding medical examination ( include BP , pulse rate ( PR ) ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 8 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 10 . Participation another trial investigational drug within two month prior administration trial 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 12 . Inability refrain smoke trial day 13 . Alcohol abuse ( 60 g/day ) 14 . Drug abuse 15 . Blood donation ( 100 mL within four week prior administration trial ) 16 . History bleed disorder acute blood coagulation defect 17 . Hypersensitivity moxifloxacin and/or relate drug class 18 . Excessive physical activity ( within one week prior administration trial ) 19 . Any laboratory value outside reference range clinical relevance 20 . Inability comply dietary regimen study centre 21 . History additional risk factor Torsade de Pointes ( e.g . heart failure , hypokalemia , family history long QT syndrome ) 22 . Any screen ECG value outside reference range clinical relevance include , limited heart rate &gt; 80 bpm &lt; 45 bpm , PR interval &gt; 220 m , QRS interval &gt; 120 m , QT interval &gt; 470 m QTcB QTcF &gt; 450 m For female subject : 23 . Pregnancy 24 . Positive pregnancy test 25 . No adequate contraception e.g . oral contraceptive , sterilisation , intrauterine device ( IUD ) 26 . Inability maintain adequate contraception whole study period 27 . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>